清肺化痰丸辅助治疗急性加重期慢性阻塞性肺疾病40例的疗效评估  

Evaluation of Therapeutic Effect of Qingfei Huatan Pills in the Treatment of 40 Cases of Acute Exacerbation Chronic Obstructive Pulmonary Disease

作　　者：余嗣崇[1] YU Sichong(Jiaozuo Second People's Hospital,Jiaozuo Henan 454000,China)

机构地区：[1]焦作市第二人民医院,河南焦作454000

出　　处：《药品评价》2022年第10期629-632,共4页Drug Evaluation

摘　　要：目的:评估清肺化痰丸作为急性加重期慢性阻塞性肺疾病(AECOPD)患者辅助治疗的有效性和安全性。方法:选取2018年12月至2019年12月于焦作市第二人民医院接受治疗的80例AECOPD患者,依据双盲法分为对照组(40例)与观察组(40例)。对照组予以常规药物治疗,观察组在常规药物治疗基础上予以清肺化痰丸治疗。主要终点是COPD评估测试(CAT)评分。次要终点包括改良的英国医学研究委员会问卷(mMRC)、COPD患者报告结果量表(COPD-PRO)、住院时间、急性加重患者人数、因AECOPD再次入院的患者人数。结果:观察组CAT评分、mMRC评分、COPD-PRO评分、临床症状评分显著高于对照组,均差异有统计学意义(P<0.05)。观察组住院时间、COPD病情加重、AECOPD重新住院患者人数显著低于对照组,差异有统计学意义(P<0.05)。观察组胸闷2例显著低于对照组胸闷8例,差异有统计学意义(P<0.05)。两组胸闷、腹泻、头昏、食欲丧失患者人数对比,差异无统计学意义(P>0.05)。结论:清肺化痰丸对AECOPD是安全和有益的,可以考虑作为AECOPD患者的补充治疗。Objective:To evaluate the effectiveness and safety of qingfei huatan pills as an adjuvant treatment for patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:A total of 80 AECOPD patients who were treated in Jiaozuo Second People’s Hospital from December 2018 to December 2019 were selected and divided into control group(40 cases)and observation group(40 cases)according to the double-blind method.The control group was given conventional drug treatment,while the observation group was given qingfei huatan pills on the basis of conventional drug treatment.The primary endpoint is the COPD assessment test(CAT)score.Secondary endpoints include the modified British Medical Research Council(mMRC)questionnaire,the COPD patient report outcome scale(COPD-PRO),length of stay,number of patients with acute exacerbations and number of patients readmitted to hospital due to AECOPD.Results:CAT score,mMRC score,COPD-PRO score and clinical symptom score in the observation group were significantly higher than those in the control group(P<0.05).The length of stay,exacerbation of COPD and the number of re hospitalized patients with AECOPD in the observation group were significantly lower than those in the control group(P<0.05).There were 2 cases of chest tightness in the observation group,which was significantly lower than 8 cases of chest tightnessin the control group(P<0.05).There was no significant difference in the number of patients with chest tightness,diarrhea,dizziness and loss of appetite between the two groups(P>0.05).Conclusion:Qingfei huatan pillsis safe and beneficial for AECOPD and can be considered as a complementary treatment for AECOPD patients.

关 键 词：肺疾病 慢性阻塞性 清肺化痰丸 支气管扩张药 

分 类 号：R563.9[医药卫生—呼吸系统]